ReviewNature reviews. Clinical oncology2010
Innovations in the systemic therapy of prostate cancer.
Review in Nature reviews. Clinical oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 24 citations in OpenAlex.
- Increased expression of microRNA-93 correlates with progression and prognosis of prostate cancer.Medicine · 2020Observational
- Long Non-Coding RNA DARS-AS1 Contributes to Prostate Cancer Progression Through Regulating the MicroRNA-628-5p/MTDH Axis.Cancer management and research · 2020Article
- MicroRNA-1291 mediates cell proliferation and tumorigenesis by downregulating MED1 in prostate cancer.Oncology letters · 2019Article
- Establishing prostate cancer patient derived xenografts: lessons learned from older studies.The Prostate · 2015Article
- An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2.British journal of pharmacology · 2013Article
- Epigenetic mechanisms in commonly occurring cancers.DNA and cell biology · 2012Review
- Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer.Neoplasia (New York, N.Y.) · 2012Article
- Methoxychalcone inhibitors of androgen receptor translocation and function.Bioorganic & medicinal chemistry letters · 2012Article
- Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion.Molecular cancer · 2012Article
- BAG3 is required for IKKα nuclear translocation and emergence of castration resistant prostate cancer.Cell death & disease · 2011Article
- [11C]Choline as pharmacodynamic marker for therapy response assessment in a prostate cancer xenograft model.European journal of nuclear medicine and molecular imaging · 2010Article
- Metronomic chemotherapy for metastatic prostate cancer: a 'young' concept for old patients?Drugs & aging · 2010Review
- Vaccines as monotherapy and in combination therapy for prostate cancer.Clinical and translational science · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic therapy has become an increasingly important component of treatment of advanced prostate cancer. In the past decade, important innovations have been achieved in the development of novel systemic hormonal therapies for the salvage treatment of metastatic castrate-resistant disease. These improvements have been accompanied by the broadening of potential indications for chemotherapy in castrate-resistant metastatic disease and the use of chemotherapy as an adjunct to the treatment of locally extensive tumors. These changes have begun to lead to improved outcomes, but at the expense of novel patterns of late toxic effects. We review the key steps in the recent evolution of systemic therapy of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.